View in EDS

Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.

Saved in:
Bibliographic Details
Title: Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
Authors: Park SS; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea. pssooni.park@samsung.com.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. pssooni.park@samsung.com.; Medical Research Institute, Kangbuk Samsung Hospital, Seoul, Republic of Korea. pssooni.park@samsung.com., Lee HW; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kwon MR; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea., Ju EJ; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea., Shin SH; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea., Park J; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea., Ko EJ; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea., Son GW; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim YJ; Department of Radiation Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Moon GJ; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Center for Cell Therapy, ASAN Medical Center, Seoul, Republic of Korea., Kim DH; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Choi YJ; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Rho JK; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Park YY; Department of Life Science, Chung-Ang University, Seoul, Republic of Korea., Kim TW; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.; Department of Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Song SY; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. coocoori@amc.seoul.kr.; Department of Radiation Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. coocoori@amc.seoul.kr., Jeong SY; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea. syj@amc.seoul.kr.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. syj@amc.seoul.kr.; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. syj@amc.seoul.kr.
Source: British journal of cancer [Br J Cancer] 2026 May 26. Date of Electronic Publication: 2026 May 26.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42185638
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Park+SS%22">Park SS</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea. pssooni.park@samsung.com.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. pssooni.park@samsung.com.; Medical Research Institute, Kangbuk Samsung Hospital, Seoul, Republic of Korea. pssooni.park@samsung.com.<br /><searchLink fieldCode="AU" term="%22Lee+HW%22">Lee HW</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kwon+MR%22">Kwon MR</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ju+EJ%22">Ju EJ</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Shin+SH%22">Shin SH</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+J%22">Park J</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ko+EJ%22">Ko EJ</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Son+GW%22">Son GW</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.; Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+YJ%22">Kim YJ</searchLink>; Department of Radiation Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Moon+GJ%22">Moon GJ</searchLink>; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Center for Cell Therapy, ASAN Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+DH%22">Kim DH</searchLink>; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+YJ%22">Choi YJ</searchLink>; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Rho+JK%22">Rho JK</searchLink>; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+YY%22">Park YY</searchLink>; Department of Life Science, Chung-Ang University, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+TW%22">Kim TW</searchLink>; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea.; Department of Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Song+SY%22">Song SY</searchLink>; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. coocoori@amc.seoul.kr.; Department of Radiation Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. coocoori@amc.seoul.kr.<br /><searchLink fieldCode="AU" term="%22Jeong+SY%22">Jeong SY</searchLink>; Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea. syj@amc.seoul.kr.; Asan Preclinical Evaluation Center for Cancer Therapeutix, ASAN Medical Center, Seoul, Republic of Korea. syj@amc.seoul.kr.; Department of Convergence Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. syj@amc.seoul.kr.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2026 May 26. <i>Date of Electronic Publication: </i>2026 May 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42185638
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-026-03475-1
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Park SS
      – PersonEntity:
          Name:
            NameFull: Lee HW
      – PersonEntity:
          Name:
            NameFull: Kwon MR
      – PersonEntity:
          Name:
            NameFull: Ju EJ
      – PersonEntity:
          Name:
            NameFull: Shin SH
      – PersonEntity:
          Name:
            NameFull: Park J
      – PersonEntity:
          Name:
            NameFull: Ko EJ
      – PersonEntity:
          Name:
            NameFull: Son GW
      – PersonEntity:
          Name:
            NameFull: Kim YJ
      – PersonEntity:
          Name:
            NameFull: Moon GJ
      – PersonEntity:
          Name:
            NameFull: Kim DH
      – PersonEntity:
          Name:
            NameFull: Choi YJ
      – PersonEntity:
          Name:
            NameFull: Rho JK
      – PersonEntity:
          Name:
            NameFull: Park YY
      – PersonEntity:
          Name:
            NameFull: Kim TW
      – PersonEntity:
          Name:
            NameFull: Song SY
      – PersonEntity:
          Name:
            NameFull: Jeong SY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 05
              Text: 2026 May 26
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1